FibroGen (NASDAQ: FGEN) reported Q2 EPS of $0.83, $0.10 better than the analyst estimate of $0.73. Revenue for the quarter came in at $120.55 million versus the consensus estimate of $111.75 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.